Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones

Neuropharmacology

Volumn 73, Issue , 2013, Pages 138-146

  Wild, A R ^a,b   Akyol, E ^a   Brothwell, S L C ^a   Kimkool, P ^a   Skepper, J N ^a   Gibb, A J ^b   Jones, S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Excitotoxicity; Use dependent antagonist

Indexed keywords

DIZOCILPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXCITATORY POSTSYNAPTIC POTENTIAL; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

EXCITOTOXICITY; USE-DEPENDENT ANTAGONIST;

ANIMALS; CELL COUNT; DIZOCILPINE MALEATE; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; MALE; MEMANTINE; N-METHYLASPARTATE; NERVE DEGENERATION; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84885165170     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.05.013     Document Type: Article

References (65)

1. Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A., Nicotera, P., 1995. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15 (4), 961-973.
2. Arias-Montaño, J.A., Martínez-Fong, D., Aceves, J., 1992. Glutamate stimulation of tyrosine hydroxylase is mediated by NMDA receptors in the rat striatum. Brain Res. 569, 317-322.
3. Blandini, F., Nappi, G., Tassorelli, C, Martignoni, E., 2000. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62 (1), 63-88. (Pubitemid 30252017)
4. Blanpied, T.A., Boeckman, F.A., Aizenman, E., Johnson, J.W., 1997. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77, 309-323. (Pubitemid 27053786)
5. Bobrovskaya, L, Dunkley, P.R., Dickson, P.W., 2004. Phosphorylation of Ser19 increases both Ser40 phosphorylation and enzyme activity of tyrosine hydroxylase in intact cells. J. Neurochem. 90, 857-864. (Pubitemid 39099967)
6. Bresink, I., Benke, T.A., Collett, V.J., Seal, A.J., Parsons, CG., Henley, J.M., Collingridge, G.L., 1996. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br. J. Pharmacol. 119, 195-204. (Pubitemid 26326448)
7. Brothwell, S.LC, Barber, J.L., Monaghan, D.T., Jane, D.E., Gibb, A.J., Jones, S., 2008. NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones. J. Physiol. 586, 739-750. (Pubitemid 351194114)
8. Bywood, P.T., Johnson, S.M., 2000. Differential vulnerabilities of substantia nigra catecholamine neurons to excitatory amino acid-induced degeneration in rat midbrain slices. Exp. Neurol. 162, 180-188. (Pubitemid 30170110)
9. Chen, H.S., Lipton, S.A., 2006. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97, 1611-1626. (Pubitemid 43873656)
10. Chen, H.S., Lipton, S.A., 1997. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. 499 (Pt 1), 27-46. (Pubitemid 27098863)
11. Chen, H.S., Wang, Y.F., Rayudu, P.V., Edgecomb, P., Neill, J.C., Segal, M.M., Lipton, S.A., Jensen, F.E., 1998. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86, 1121-1132. (Pubitemid 28318538)
12. Chowdhury, M., Fillenz, M., 1991. Presynaptic adenosine A2 and N-methyl-D-aspartate receptors regulate dopamine synthesis in rat striatal synaptosomes. J. Neurochem. 56, 1783-1788.
13. Cull-Candy, S.G., Leszkiewicz, D.N., 2004. Role of distinct NMDA receptor subtypes at central synapses. Sci. STKE 255, re16.
14. Danysz, W., Parsons, C.G., Kornhuber, J., Schmidt, W.J., Quack, G., 1997. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev. 21, 455-468. (Pubitemid 27255850)
15. Danysz, W., Parsons, C.G., Quack, G., 2000. NMDA channel blockers: memantine and amino-aklylcyclohexanes - in vivo characterization. Amino Acids 19, 167-172.
16. Desce, J.M., Godeheu, G., Galli, T., Glowinski, J., Cheramy, A., 1994. Opposite pre-synaptic regulations by glutamate through NMDA receptors of dopamine synthesis and release in rat striatal synaptosomes. Brain Res. 640, 205-214. (Pubitemid 24086548)
17. Doble, A., 1999. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163-221. (Pubitemid 29094735)
18. Fallon, J.H., Loughlin, S.E., 1995. Substantia nigra. In: Paxinos, G. (Ed.), The Rat Nervous System, second ed. Academic Press.
19. Frankiewicz, T., Potier, B., Bashir, Z.I., Collingridge, G.L., Parsons, C.G., 1996. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. 117, 689-697. (Pubitemid 26070246)
20. Gilling, K.E., Jatzke, C., Parsons, C.G., 2007. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine. Neuropharmacology 53, 415-420. (Pubitemid 47212248)
21. Gwag, B.J., Koh, J.Y., DeMaro, J.A., Ying, H.S., Jacquin, M., Choi, D.W., 1997. Slowly triggered excitotoxicity occurs by necrosis in cortical cultures. Neuroscience 77, 393-401. (Pubitemid 27079611)
22. Hallett, P.J., Standaert, D.G., 2004. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 102, 155-174. (Pubitemid 38681014)
23. Hardingham, G.E., Bading, H., 2010. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682-696.
24. Hardingham, G.E., Fukunaga, Y., Bading, H., 2002. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405-414. (Pubitemid 34454245)
25. 2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J. Neurosci. 13, 1993-2000. (Pubitemid 23113411)
26. Hesselink, M.B., De Boer, B.G., Breimer, D.D., Danysz, W., 1999. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm. Res. 16, 637-642. (Pubitemid 29227091)
27. Higley, M.J., Soler-Llavina, G.J., Sabatini, B.L., 2009. Cholinergic modulation of multivesicular release regulates striatal synaptic potency and integration. Nat. Neurosci. 12, 1121-1128.
28. Hutchison, W.D., Allan, R.J., Opitz, H., Levy, R., Dostrovsky, J.O., Lang, A.E., Lozano, A.M., 1998. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann. Neurol. 44, 622-628. (Pubitemid 28477849)
29. Johnson, S.M., Bywood, P.T., 1998. Excitatory amino acid-induced degeneration of dendrites of catecholamine neurons in rat substantia nigra. Exp. Neurol. 151, 229-236. (Pubitemid 28285903)
30. Johnson, J.W., Kotermanski, S.E., 2006. Mechanism of action of memantine. Curr. Opin. Pharmacol. 6, 61-67. (Pubitemid 43103820)
31. Jones, S., Gibb, A.J., 2005. Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J. Physiol. 569, 209-221. (Pubitemid 41701386)
32. Kashiwagi, K., Masuko, T., Nguyen, C.D., Kuno, T., Tanaka, I., Igarashi, K., Williams, K., 2002. Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol. Pharmacol. 61 (3), 533-545. (Pubitemid 34171919)
33. Kemp, J.A., McKernan, R.M., 2002. NMDA receptor pathways as drug targets. Nat. Neurosci. 5, 1039-1042. (Pubitemid 35247194)
34. 2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J. Neurosci. 29, 2774-2779.
35. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B., Charney, D.S., 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214. (Pubitemid 24081509)
36. Lau, C.G., Zukin, R.S., 2007. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8, 413-426. (Pubitemid 46789232)
37. Lipton, S.A., 2004. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1, 101-110. (Pubitemid 46589343)
38. Lipton, S.A., 2006. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5, 160-170.
39. Lipton, S.A., 2007. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 8, 803-808. (Pubitemid 47462118)
40. Lisman, J.E., Raghavachari, S., Tsien, R.W., 2007. The sequence of events that underlie quantal transmission at central glutamatergic synapses. Nat. Rev. Neurosci. 8, 597-609. (Pubitemid 47093933)
41. Litvinenko, I.V., Odinak, M.M., Mogil'naya, V.I., Perstnev, S.V., 2010. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neurosci. Behav. Physiol. 40, 149-155.
42. Low, S.J., Roland, C.L., 2004. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int. J. Clin. Pharmacol. Ther. 42, 1-14. (Pubitemid 38100854)
43. MacDonald, J.F., Bartlett, M.C., Mody, I., Pahapill, P., Reynolds, J.N., Salter, M.W., Schneiderman, J.H., Pennefather, P.S., 1991. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J. Physiol. 432, 483-508.
44. Magariños-Ascone, C.M., Figueiras-Mendez, R., Riva-Meana, C., Córdoba-Fernández, A., 2000. Subthalamic neuron activity related to tremor and movement in Parkinson's disease. Eur. J. Neurosci. 12, 2597-2607. (Pubitemid 30497053)
45. Magnin, M., Morel, A., Jeanmonod, D., 2000. Single-unit analysis of the pallidum, thalamus and subthalamic nucleus in parkinsonian patients. Neuroscience 96, 549-564. (Pubitemid 30136320)
46. Margolis, E.B., Lock, H., Hjelmstad, G.O., Fields, H.L., 2006. The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? J. Physiol. 577, 907-924. (Pubitemid 44873655)
47. Munhall, A.C., Wu, Y.N., Belknap, J.K., Meshul, C.K., Johnson, S.W., 2012. NMDA alters rotenone toxicity in rat substantia nigra zona compacta and ventral tegmental area dopamine neurons. Neurotoxicology 33, 429-435.
48. Neuhoff, H., Neu, A., Liss, B., Roeper, J., 2002. I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J. Neurosci. 22, 1290-1302. (Pubitemid 34163731)
49. 2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. Neuropharmacology 60, 388-396.
50. Papadia, S., Soriano, F.X., Léveillé, F., Martel, M.A., Dakin, K.A., Hansen, H.H., Kaindl, A., Sifringer, M., Fowler, J., Stefovska, V., McKenzie, G., Craigon, M., Corriveau, R., Ghazal, P., Horsburgh, K., Yankner, B.A., Wyllie, D.J., Ikonomidou, C., Hardingham, G.E., 2008. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 11, 476-487. (Pubitemid 351441886)
51. Parsons, C.G., Gilling, K.E., Jatzke, C., 2008. Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes. J. Neural Transm. 115, 1367-1373, 1996.
52. Parsons, C.G., Stöffler, A., Danysz, W., 2007. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 53, 699-723. (Pubitemid 47532143)
53. Piallat, B., Polosan, M., Fraix, V., Goetz, L., David, O., Fenoy, A., Torres, N., Quesada, J.L., Seigneuret, E., Pollak, P., Krack, P., Bougerol, T., Benabid, A.L., Chabardès, S., 2011. Subthalamic neuronal firing in obsessiveecompulsive disorder and Parkinson disease. Ann. Neurol. 69, 793-802.
54. Pomarol-Clotet, E., Honey, G.D., Murray, G.K., Corlett, P.R., Absalom, A.R., Lee, M., McKenna, P.J., Bullmore, E.T., Fletcher, P.C., 2006. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br. J. Psychiatry 189, 173-179. (Pubitemid 44231278)
55. Puzin, M.N., Krivonos, O.V., Kozhevnikova, Z.V., 2007. Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 95, 93-97.
56. Rabey, J.M., Nissipeanu, P., Korczyn, A.D., 1992. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 4, 277-282.
57. Sohn, S., Kim, E.Y., Gwag, B.J., 1998. Glutamate neurotoxicity in mouse cortical neurons: atypical necrosis with DNA ladders and chromatin condensation. Neurosci. Lett. 240, 147-150. (Pubitemid 28079043)
58. Steigerwald, F., Pötter, M., Herzog, J., Pinsker, M., Kopper, F., Mehdorn, H., Deuschl, G., Volkmann, J., 2008. Neuronal activity of the human subthalamic nucleus in the parkinsonian and nonparkinsonian state. J. Neurophysiol. 100, 2515-2524.
59. Suárez, F., Zhao, Q., Monaghan, D.T., Jane, D.E., Jones, S., Gibb, A.J., 2010. Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones. Eur. J. Neurosci. 32, 359-367.
60. Volbracht, C., Van Beek, J., Zhu, C., Blomgren, K., Leist, M., 2006. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur. J. Neurosci. 23, 2611-2622. (Pubitemid 43801453)
61. De Vry, J., Jentzsch, K.R., 2003. Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav. Pharmacol. 14, 229-235. (Pubitemid 36735156)
62. Washio, H., Takigachi-Hayashi, K., Konishi, S., 1999. Early postnatal development of substantia nigra neurons in rat midbrain slices: hyperpolarization-activated inward current and dopamine-activated current. Neurosci. Res. 34, 91-101. (Pubitemid 29378297)
63. Wedzony, K., Fija1, K., Chocyk, A., 2005. Blockade of NMDA receptors in postnatal period decreased density of tyrosine hydroxylase immunoreactive axonal arbors in the medial prefrontal cortex of adult rats. J. Physiol. Pharmacol. 56, 205-221. (Pubitemid 40911088)
64. Wroge, C.M., Hogins, J., Eisenman, L., Mennerick, S., 2012. Synaptic NMDA receptors mediate hypoxic excitotoxic death. J. Neurosci. 32, 6732-6742.
65. Xia, P., Chen, H.-S.V., Zhang, D., Lipton, S.A., 2010. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 30, 11246-11250.